NFE2L2 and cancer: Cancers with NRF2 hyperactivating mutations share a set of upregulated target genes, including key regulators involved in the thioredoxin and glutathione system, metabolic enzymes, transporters, and others, enabling a cancer growth advantage and consequently a worse overall survival.